Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4 ...

Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

Elizabeth Krutoholow; VP, Investor Relations; Tempus AI Inc. Jim Rogers; Chief Financial Officer; Tempus AI Inc. Eric Lefkofsky; Chief Executive Officer, Director; T ...

Tempus AI Inc (TEM) reports a 75.4% revenue increase and a significant $200 million partnership, setting the stage for a promising fiscal year.

CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% year-over-year to $255.7 million. Genomics revenue grew 89% year-over-year to $193.8 million ...

Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.